WO2001055330A2 - Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire - Google Patents

Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire Download PDF

Info

Publication number
WO2001055330A2
WO2001055330A2 PCT/US2001/001989 US0101989W WO0155330A2 WO 2001055330 A2 WO2001055330 A2 WO 2001055330A2 US 0101989 W US0101989 W US 0101989W WO 0155330 A2 WO0155330 A2 WO 0155330A2
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
virus
envelope protein
immunodeficiency
subunit
Prior art date
Application number
PCT/US2001/001989
Other languages
English (en)
Other versions
WO2001055330A3 (fr
Inventor
Matthias J. Schnell
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Priority to JP2001561135A priority Critical patent/JP2003535577A/ja
Priority to CA002396709A priority patent/CA2396709A1/fr
Priority to EP01946888A priority patent/EP1255849A2/fr
Priority to AU2001229677A priority patent/AU2001229677A1/en
Publication of WO2001055330A2 publication Critical patent/WO2001055330A2/fr
Publication of WO2001055330A3 publication Critical patent/WO2001055330A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

L'invention concerne des vecteurs d'expression, à base de souches vaccinales de Rhabdovirus, capables de réplication, recombinés et destinés à exprimer des polypeptides antigéniques viraux hétérologues, tels que les protéines d'enveloppe de virus à déficit immunitaire, ou des sous-parties de celles-ci. On a inséré une unité supplémentaire de départ/arrêt de transcription dans le génome des Rhabdovirus, aux fins d'expression desdits polypeptides antigéniques hétérologues. La protéine gp 160 du VIH-1 est exprimée de façon stable et fonctionnelle, comme indiqué par la fusion des lignées de lymphocytes T humains, après infection par des Rhabdovirus recombinés. L'inoculation de souris à l'aide des virus de la rage recombinés et exprimant la protéine gp 160 du VIH-1 induit une forte réponse humorale dirigée contre la protéine d'enveloppe du VIH-1 après une seule stimulation à l'aide d'une protéine gp 120 du VIH-1 recombinée et isolée. En outre, on a détecté chez ces souris des taux sériques élevés de neutralisation du VIH-1, pouvant aller jusqu'à 1/800. Ces vecteurs viraux recombinés exprimant des polypeptides antigéniques viraux constituent des compositions pharmaceutiques utiles et efficaces dans la production de réponses immunes, spécifiques des virus.
PCT/US2001/001989 2000-01-28 2001-01-22 Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire WO2001055330A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001561135A JP2003535577A (ja) 2000-01-28 2001-01-22 免疫不全ウイルス用生ウイルスワクチンとしての組換えラブドウイルス
CA002396709A CA2396709A1 (fr) 2000-01-28 2001-01-22 Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire
EP01946888A EP1255849A2 (fr) 2000-01-28 2001-01-22 Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire
AU2001229677A AU2001229677A1 (en) 2000-01-28 2001-01-22 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49426200A 2000-01-28 2000-01-28
US09/494,262 2000-01-28

Publications (2)

Publication Number Publication Date
WO2001055330A2 true WO2001055330A2 (fr) 2001-08-02
WO2001055330A3 WO2001055330A3 (fr) 2002-03-28

Family

ID=23963758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001989 WO2001055330A2 (fr) 2000-01-28 2001-01-22 Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire

Country Status (6)

Country Link
EP (1) EP1255849A2 (fr)
JP (1) JP2003535577A (fr)
CN (1) CN1416471A (fr)
AU (1) AU2001229677A1 (fr)
CA (1) CA2396709A1 (fr)
WO (1) WO2001055330A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1322119C (zh) * 2002-11-14 2007-06-20 中国科学院水生生物研究所 鳜鱼弹状病毒毒株及制备方法和应用
US7541038B2 (en) 2003-06-05 2009-06-02 Wyeth Holdings Corporation Fusogenic, self-propagating blebs as immunogenic compositions
CN106802348A (zh) * 2016-12-30 2017-06-06 广东华南联合疫苗开发院有限公司 Sf弹状病毒N蛋白双抗夹心酶联免疫检测试剂盒及方法
US9889192B2 (en) 2012-10-01 2018-02-13 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105441483B (zh) * 2005-10-14 2019-05-10 美国政府健康及人类服务部，疾病控制和预防中心 狂犬病病毒组合物和方法
US20100278864A1 (en) * 2005-12-14 2010-11-04 University Of Georgia Research Foundation, Inc. Rabies Vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1322119C (zh) * 2002-11-14 2007-06-20 中国科学院水生生物研究所 鳜鱼弹状病毒毒株及制备方法和应用
US7541038B2 (en) 2003-06-05 2009-06-02 Wyeth Holdings Corporation Fusogenic, self-propagating blebs as immunogenic compositions
US9889192B2 (en) 2012-10-01 2018-02-13 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
CN106802348A (zh) * 2016-12-30 2017-06-06 广东华南联合疫苗开发院有限公司 Sf弹状病毒N蛋白双抗夹心酶联免疫检测试剂盒及方法

Also Published As

Publication number Publication date
CA2396709A1 (fr) 2001-08-02
WO2001055330A3 (fr) 2002-03-28
JP2003535577A (ja) 2003-12-02
EP1255849A2 (fr) 2002-11-13
CN1416471A (zh) 2003-05-07
AU2001229677A1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
Mossman et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
US5714374A (en) Chimeric rhinoviruses
Stott et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine
Caley et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
Lorin et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV
Girard et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
US9844589B2 (en) Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses
Giavedoni et al. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection
Rovinski et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine
Ahmad et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus
PUTKONEN et al. Vaccine protection against HIV-2 infection in cynomolgus monkeys
Zolla-Pazner et al. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
El-Amad et al. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2
Khattar et al. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs
Rabinovich et al. A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice
Vzorov et al. Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines
Etemad-Moghadam et al. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys
Tan et al. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime–boost approach
Xiao et al. Parainfluenza virus 5 priming followed by SIV/HIV virus-like-particle boosting induces potent and durable immune responses in nonhuman primates
CZ2003784A3 (cs) Zlepšené podmíněně se replikující vektory, způsoby jejich produkce a jejich použití
VAN EENDENBURG et al. Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses
Narayan et al. Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques
ES2634144T3 (es) Vectores de transferencia lentivíricos defectuosos que no se integran para vacunas
Sheppard Inactivated-or killed-virus HIV/AIDS vaccines
WO2001055330A2 (fr) Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2396709

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 561135

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 018042295

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001946888

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946888

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001946888

Country of ref document: EP